Ambio Pharmaceuticals Group

Ambio is a private specialty pharmaceutical and biotech company focused on complex peptide drugs, biosimilars, bioequivalent products, and other complex generics. The company emphasizes peptide drug development, analytical characterization, long-acting formulations, and scale-up to commercial manufacturing, supported by proprietary know-how and a Quality by Design development approach. Ambio has highlighted a pipeline aimed at blockbuster indications in diabetes, obesity, and related areas, while also achieving commercial and regulatory milestones in complex peptide generics. Publicly disclosed programs and partnerships include teriparatide with Apotex and icatibant with Adalvo. The broader Ambio Pharmaceuticals Group also includes AmbioPharm, a peptide-focused CDMO manufacturing partner with U.S. and China capabilities.